The governments requirement is to establish a cost-per-kit agreement to include reagents, consumables, controls, and any necessary products to conduct all required testing for the chemiluminescence…
Ended Purchase Order Awarded Last action
- Contract number
- W81K0025PA125
- Awardee
-
Diasorin Inc. UEI FGK2QR959BV5 Part of Diasorin S.P.A.
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $290,946
Award facts
- Opportunity
-
- Notice of Intent to sole source for the Chemiluminescent immunoassay (CLIA) kits compatible with the government’s current CLIA instrumentation for the Brooke Army Medical Center (BAMC). Special Notice · W81K0025QA057 · Posted Apr 3, 2025
- Contract value 7% obligated
-
- $1,213,892.44 Current, with exercised options
- $3,982,732.54 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- 2330 Stanley Rd, Fort Sam Houston, TX 78234, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Funding Only Action | -$632,000 | |
| Funding Only Action | $922,946 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
About this award
The Defense Health Agency awarded a firm-fixed-price purchase order to Diasorin Inc. on October 1, 2025, with a ceiling value of $3,982,732.54, for a cost-per-kit agreement covering reagents, consumables, controls, and all necessary products for chemiluminescence immunoassay (CLIA) testing. The order carries no set-aside. Place of performance is 2330 Stanley Rd, Fort Sam Houston, TX 78234, and the period of performance runs through September 30, 2030. The order exercises the FY26 option year, transfers administration from DODAAC HT0852 to HT9408, and modifies clause 252.232-7006. The requirement originated in a Special Notice posted April 3, 2025 by Army Medical Command for Brooke Army Medical Center's Department of Pathology and Area Laboratory Services. That notice announced intent to sole source under FAR 13.501 simplified procedures, citing Diasorin as the only responder to a January 2025 sources sought notice and the only FDA-approved manufacturer offering the required assay compatible with the existing Diasorin Liaison XL instrumentation.
Description
The governments requirement is to establish a cost-per-kit agreement to include reagents, consumables, controls, and any necessary products to conduct all required testing for the chemiluminescence immunoassay (clia) reagents.
Quick answers
Who was awarded contract W81K0025PA125?
W81K0025PA125 was awarded to Diasorin Inc. by Medical Command (Department of the Army) on October 1, 2025.
How much is contract W81K0025PA125 worth?
The government has obligated $290,946 on W81K0025PA125. Its current value, with exercised options, is $1,213,892. Its potential value, with all options, is $3,982,733.
Which agency awarded contract W81K0025PA125?
Medical Command (Department of the Army) awarded W81K0025PA125, with funding from Defense Health Agency (Department of Defense).
Was contract W81K0025PA125 competed?
The extent of competition for W81K0025PA125 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award